Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fasiglifam in Type 2 Diabetes
NCT01456195Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 24 weeks. Started Nov 2011; status: completed.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01456195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01456195.